Bloomberg on MSN54m
CSL 1H Profit Misses Estimates on Weak Vaccine SalesCSL CEO Paul McKenzie has reiterated the company's revenue growth guidance, even after first-half net income of the world's second-largest manufacturer of influenza vaccines came below analysts' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback